Advances in Therapy for Gout: 2013
The Past, Present, and Future

Jonathan Graf, M.D.
Associate Professor of Clinical Medicine
UCSF
Division of Rheumatology, SFGH

Therapy for Gout: The Past
The New York Times
May 22, 1997

Pity a Tyrannosaur? Sue Had Gout
BY MALCOLM W. BROWNE

For all the suffering she probably caused her Cretaceous prey, a tyrannosaur named Sue seems to have paid dearly. Scientists have determined that the big dinosaur probably was a victim of agonizing gout and other debilitating ailments.

Gout is becoming interesting again...

Famous Sufferers of Gout

NEJM 2/11
Lancet 1/11

NEJM 2/11
Lancet 1/11

Henry VIII
Benjamin Franklin
David Wells
Sports Illustrated
III. Dialogue Between Franklin and the Gout

Benjamin Franklin (1780)

FRANKLIN. Eh! Oh! eh! What have I done to merit these cruel sufferings?

GOUT. Many things; you have ate and drank too freely, and too much indulged those legs of yours in their indolence.

FRANKLIN. Who is it that accuses me?

GOUT. It is I, even I, the Gout.

“Persons affected with the gout who are aged, have tophi in their joints, who have led a hard life, and whose bowels are constipated are beyond the power of medicine to cure” – Hippocrates c. 400 BCE

Gout is an Ancient Disease:
Hippocratic Aphorisms c. 400 BCE
Section VI

- 28. Eunuchs do not take the gout, nor become bald.
- 29. A woman does not take the gout, unless her menses be stopped.
- 30. A young man does not take the gout until he indulges in coition.

Acute Gout

- Acute, usually self limited monoarticular inflammatory arthropathy
- Inflammatory response directed against monosodium urate crystals in synovium
- Usually but not always associated with hyperuricemia
- Monosodium urate crystals precipitate around a UA concentration of 6.8, below the upper limit of “normal” in most US populations
Case I

55 year old male with a history of known gout awakens with right knee pain and swelling one morning that worsens over next 48 hours until he has difficulty walking on that knee. On a recent Chem. 20 panel, uric acid level was elevated at 10.7. He denies any other joint pains, IVDU, or recent sexual contacts.

After undergoing arthrocentesis confirming the diagnosis of gout and ruling out an infectious process, the patient is started on indomethacin and allopurinol and sent home. Which of the following treatments in this case was a mistake?

A. Allopurinol therapy  
B. Indomethacin therapy  
C. Both A&B  
D. None of the above

Acute Gout: Traditional Therapy

• Acute gout is distinguished from chronic gout
  — Self limited: Patient returns to normal during an asymptomatic inter-critical period that can last months or years
• Therapy is aimed at reducing the severity and duration of symptoms and reaching the “inter-critical period” sooner
• NSAIDs
  — Effective and rapid relief of symptoms
  — Contraindicated in patients with GI, Renal, or hypersensitivity concerns
• Corticosteroids
  — Intraarticular  
  — Systemic
• Uric Acid lowering therapy is not appropriate during acute gouty flare

Colchicine for Acute Gout – What’s the real story?

• Colchicine’s use in acute gout dates back decades
  — Dates back before the establishment of the FDA and its approval process
• Thought to inhibit microtubule formation, thereby blocking leukocyte migration into an inflamed joint
• Classically prescribed only within first 48 hours of symptoms (limits its use)
• Classically prescribed as repeating doses roughly every 2 hours until the patient develops GI toxicity or begins feeling better
• This type of therapy generally felt to be dangerous (especially in patients with renal insufficiency), inhumane, and unacceptable
FDA Initiative: Drugs in Use before creation of FDA

- Drugs in use prior to FDA approval process should be “encouraged” to be formally evaluated for safety, purity, and efficacy
- Companies receiving formal FDA approval for “old” medications rewarded with exclusivity in manufacturing, marketing, & distribution
- 2009: multiple manufacturers of generic colchicine at a cost of pennies/pill
- 2010: URL pharma, a manufacturer of generic colchicine, submitted data from a small clinical trial using its pill to treat acute gout
- FDA approved URL pharma’s version of colchicine, granted it a 3 year exclusivity to market it for gout, and ordered all other generic manufacturers to cease and desist
- Generic colchicine renamed “Colcrys” and price raised to $5/pill

$The Value of Colchicine$%

Takeda of Japan Buys URL Pharma for $800 Million

By MARK SCOTT

The Takeda Pharmaceutical Company of Japan agreed on Wednesday to buy URL Pharma for $800 million, plus potential further payments based on the company’s performance.

Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceutical

Dec. 18, 2012 – Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda’s wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) has entered into a definitive agreement with Caraco Pharmaceutical Laboratories, Ltd. (Caraco), a wholly-owned subsidiary of Sun Pharmaceutical Industries, Ltd. for the sale of the non-Colcrys (colchicine, USP) URL Pharma, Inc.* generic business. With the acquisition of URL Pharma earlier this year, Takeda has become a leader in gout therapy by adding Colcrys to its portfolio. Net sales for Colcrys totalled $155 million from June 1 to September 30, 2012.

The Clinical Value of Colchicine for Acute Gout

- FDA approval based upon one study
  - Examined “Colcrys” in acute gout
  - “High dose” vs “low dose” (0.6 mg BID) vs. placebo
  - No comparison to NSAIDs or Prednisone
  - High dose more toxic and no better than low dose
  - FDA approved “low dose” only
  - While statistically significant response, underwhelming compared to experience with other acute gout treatments

Colchicine: How Effective for Acute Gout??

<table>
<thead>
<tr>
<th>Colchicine dose</th>
<th>High (n = 52)</th>
<th>Low (n = 74)</th>
<th>Placebo (n = 36)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary endpoint</td>
<td>Treatment response based on target joint pain score: 24 hours after the first dose</td>
<td>17 (32.7)</td>
<td>28 (37.8)</td>
</tr>
<tr>
<td></td>
<td>Absolute definition of response</td>
<td>19 (36.5)</td>
<td>34 (45.9)</td>
</tr>
<tr>
<td></td>
<td>Treatment response based on at least a 2-unit reduction in target joint pain score: 24 hours after the first dose</td>
<td>18 (34.6)</td>
<td>32 (43.2)</td>
</tr>
<tr>
<td></td>
<td>Treatment response based on at least a 2-unit reduction in target joint pain score: 24 hours after the first dose</td>
<td>20 (38.5)</td>
<td>34 (45.9)</td>
</tr>
</tbody>
</table>

No matter how “response” defined, only about 40% of patients achieve primary endpoint!
Colchicine for Acute Gout: Summary

• High dose colchicine should NEVER be used to treat any patient with acute gout

• “Colcrys” brand colchicine is/will soon be the only FDA approved and available form of colchicine

• When dosed as approved (low dose/BID), the efficacy of “Colcrys” for acute gout is underwhelming

• There are much better regimens at one’s disposal, including NSAIDs and/or Prednisone

Chronic Gout - Progression

• Recurrent inflammatory arthritic attacks separated by diminishing inter-critical periods of normalcy
  – Monoarticular or polyarticular
    – Same joint
    – Spread to other joints
      – General rule of thumb: most commonly involved joints: distal (podagra) to proximal

• Chronic inflammation/synovitis with no inter-critical period
  – Recurrent attacks blend together and patient’s symptoms never return entirely to normal between attacks
  – Eventually, chronic inflammation remains

• Tophaceous gout:
  – Can occur with all of the above
  – Uric acid containing tophi deposit in joints/tendons/soft tissues, can lead to erosions and deformities
  – Chronic synovitis and tophaceous deformities can be difficult to distinguish from other inflammatory arthritis such as RA

Chronic Gout – Traditional Management

• Goal: reduce serum uric acid level, but not during an acute attack!!!
  – Lower serum urate levels are associated with fewer attacks
  – Helps remove tophi/stores of uric acid
  – Target serum urate levels below crystallization concentration (< 6.0 or even 5.0 if possible) to reabsorb tophi
  – Max. dose of allopurinol is 300 mg/day
  – Many patients with normal renal function can be given higher doses
  – New therapies available to get uric acid levels to target

• Prophylaxis
  – Prophylax against acute gout flares when initiating or adjusting uric acid lowering therapy
  – Colchicine does work well for this (unfortunately, it now costs $3/pill)
  – NSAIDs and prednisone work as well

Chronic Gout – Serum Urate Lowering Therapies

• Probencid:
  – Uricosuric agent blocks tubular re-absorption of uric acid
  – Useful in patients who under-excrete uric acid (90%)
  – If need be, confirm under-excretion with 24 hr. uric acid <800 mg/24 hrs.
  – Do not use if:
    – Tophi
    – Renal insufficiency
    – Clear overproduction syndrome
Chronic Gout – Serum Urate Lowering Therapies

- Allopurinol
  - Xanthine Oxidase Inhibitor
  - Blocks metabolism of purines to uric acid
  - Effective for both under-excreters and overproducers of uric acid

Allopurinol is a purine derivative: a dead ringer for hypoxanthine

Allopurinol competes with Hypoxanthine for xanthine oxidase

Purine Metabolism

Allopurinol Toxicities

- Careful use in patients with renal failure
  - Metabolites are renally cleared
  - Hypersensitivity reactions are more common in patients with renal insufficiency
- Purine-associated hypersensitivity syndrome is different from allergic rash
  - Systemic and sometimes life threatening illness
  - Fever, Steven’s-Johnson/TEN, hepatitis, marrow suppression, nephritis
The Present State of Gout Therapy: What to do with a More Challenging Case?

You are seeing a 56 year old male with long standing diabetes, hypertension, chronic renal insufficiency, and destructive tophaceous gout. His gout originally began as episodic podagra that became more frequent and involved more joints over time. In the past few years, his tophi have grown larger and more numerous, and acute episodes of inflammatory arthritis have begun to blend together into a chronic, painful, polyarticular inflammatory synovitis in his hands, elbows, knees, and feet from which he has come to your office seeking relief.

Gout: Findings

- He has chronic swelling, synovitis, and deformities reminiscent of rheumatoid arthritis
- Numerous tophi scattered on arms, legs, and ears
- Serum creatinine is 1.8
- Uric Acid 10.2

You face two problems:

- What to do to treat his symptoms acutely?
- How to manage his now chronic arthropathy in the longer-term?

Managing the Chronic Disease

Once his acute symptoms have improved and he has been adequately prophylaxed against further exacerbations, you now decide to treat his chronic symptoms of gout by:

A. Starting allopurinol 300/day
B. Colchicine 0.6 mg/day
C. Probenecid 250 mg twice daily
D. None of the above
Management of Chronic Gout in a Challenging Patient

You decide to start allopurinol therapy carefully, by beginning with 100 mg QoD and progressing over SEVERAL months to as much as 300 mg QOD. However, the patient develops a fever, rash, and elevated LFTs thought secondary to allopurinol hypersensitivity that necessitates discontinuing the medication. The patient recovers fully and now has a uric acid level of 9.1. His chronic destructive arthritis continues unabated.

Your next Best Step is...

A. To try allopurinol desensitization
B. Ban him from eating all foods with purines
C. Give up
D. Hope that Big Pharma will have an answer.....

Febuxostat (FDA approved 2009)

- First treatment in 40 years in chronic management of gout
- NON-PURINE inhibitor of xanthine oxidase
- Theoretically safe to use in patients with allopurinol reactions
- Been studied in patients with mild renal insufficiency
- Dosed at 40-80mg/once daily

Fubuxostat is Not a Purine
Comparison of Febuxostat to Allopurinol
Becker et al. NEJM 2005

- 80mg and 120mg of febuxostat superior to allopurinol 300mg/day
  - Percent of patients achieving uric acid <6
  - Greater reduction in serum uric acid levels
- Used in patients with mild-moderate renal insufficiency (SCR <1.5 in this study)
- "Safe" for patients with allopurinol reactions
  - Note: Allopurinol 300/day is probably suboptimal dose for many patients

<table>
<thead>
<tr>
<th>Table 3. Primary and Secondary End Points.</th>
</tr>
</thead>
<tbody>
<tr>
<td>End Point</td>
</tr>
<tr>
<td>Primary end point</td>
</tr>
<tr>
<td>Serum urate level (&lt;6mg/dl at least 3 monthly visits)</td>
</tr>
<tr>
<td>Difference in proportions, 80mg Febuxostat vs. Allopurinol — 6%</td>
</tr>
<tr>
<td>Secondary end point</td>
</tr>
<tr>
<td>Serum urate level (&lt;6mg/dl at final visit)</td>
</tr>
<tr>
<td>Difference in proportions, 80mg Febuxostat vs. Allopurinol — 6%</td>
</tr>
</tbody>
</table>

Febuxostat: Summary

- More potent than 300mg/day allopurinol (but many patients can tolerate higher doses of allopurinol)
- As it is not a purine: Appropriate for patients with allopurinol hypersensitivity
- Can be used safely in patients with mild renal insufficiency (unlike allopurinol)
Febuxostat: Summary

- Cannot be used concomitantly with purine based medicines that are metabolized by xanthine oxidase (leads to toxic levels of 6MP, for example)
- Use should be reserved for those not controlled by or who have a contraindication to maximal allopurinol therapy

Severe Tophaceous Gout:

Lifetime of standard uric acid lowering treatment won’t eliminate these tophi

What if.....

- You could convert relatively insoluble uric acid to a more soluble and excretable metabolite?
- You could achieve a sustained reduction in uric acid levels below 5?
- You were a pig? (Pigs don’t get gout)
- You could reverse-engineer evolution?

Uricase

- Enzyme that converts insoluble uric acid to more soluble metabolite allantoin
- Most of animal kingdom (& many mammals) posses uricase, but not humans have lost gene function
- Rasburicase: a drug derived from aspergillis used to treat tumor lysis syndrome in pediatric leukemia
- Rasburicase is extremely immunogenic, which limits its half life and use in chronic diseases
Pegloticase (FDA approval Sept. 2010)

- Mammalian uricase
- Pegylated
  - Increases half life
  - Reduces immunogenicity
- Administered by IV infusion every 2 weeks

Efficacy of Pegloticase
Sundy et al. A&R 2008

- Phase 2 randomized open label dose ranging study 41 patients with serum urate >8
- Intolerance or inadequate response to standard urate lowering therapy (UA>6) for at least 3 months
- Plus one of the following:
  - At least one tophus
  - At least one flare in last 6 months
  - Chronic gouty arthropathy

Efficacy of Pegloticase
Phase 2 (12 week) open label dosing trial 41 patients

Purine Metabolism

Nature Reviews | Drug Discovery
Pegloti – CASE
Baraf et al. A&R 2008

- 70-year-old man with a 25-year history of gout
- Urate level of 9.2 mg/dl
- 20 gout flares in the 12 months
- Visible tophi on both hands.
- History of nephrolithiasis, renal insufficiency, hypercholesterolemia
- Patient received six q2 wk. infusions of pegloticase

- 24 hours after first infusion, his urate level decreased to <0.1 mg/dl and remained at <0.1 mg/dl until 2 weeks after the final infusion.

Visible Results

Pegloticase: Not holy grail

- Adverse evets:
  - Infusion reactions (not human, even with PEG)
  - Anaphylaxis
  - 80% patients had gout flares despite prophylaxis
  - Contraindicated in G6PD deficient patients
  - May exacerbate CHF

Pegloticase: Not holy grail

- 2 Randomized double blind 6 month FDA approval trials (212 patients, 71% with tophi):
  - 38-47% of patients on 8 mg q2 wks reached primary endpoint (UA<6 80% time at months 3&6) compared to 0% placebo
  - 45% of patients “complete” resolution of at least one tophus without progression or formation of other tophi
    - 81% of responders who reached endpoint had tophus resolution
  - Many patients develop antibodies to drug that increases its clearance and effects its efficacy
Pegloticase: Summary

- Effective agent for acute lowering and chronic reduction in serum uric acid levels
- Serum uric acid levels are low enough in some patients to promote tophus resorption
- Medication is expensive, immunogenic, and associated with adverse events
- Refer these patients with severe tophaceous gout to rheumatologists!!

Gout Therapy: The Future

Renal excretion of uric acid

Target #1: URAT 1 Enhancing Uric Acid Secretion

Back to our Challenging Case....

- He has chronic swelling, synovitis, and deformities reminiscent of rheumatoid arthritis
- Numerous tophi scattered on arms, legs, and ears
- Serum creatinine is 1.8
- Uric Acid 10.2
- Diabetes

You face two problems:

- What to do to treat his symptoms acutely?
- How to manage his now chronic arthropathy in the longer-term?

Managing the Acute Symptoms

In the acute setting, the best approach to managing this patient’s symptoms would be to start:

A. Indomethacin 75 mg-100mg PO TID
B. Colchicine 0.6 mg PO q2hr until he improves
C. Prednisone 20 mg PO QD
D. Allopurinol 300 mg PO QD

Managing the Acute Symptoms

A. Indomethacin 75 mg-100mg PO TID
   - Can’t use because of renal disease
B. Colchicine 0.6 mg PO q2hr until he improves
   - Not standard of care for acute gout
C. Prednisone 20 mg PO QD
   - Best choice, but not ideal given diabetes
D. Allopurinol 300 mg PO QD
   - Not used to treat acute inflammation

Are there any anti-inflammatory treatments on the horizon for those refractory to or intolerant of standard therapy??
Therapy for Acute Gout: A “Biologic” Future??

Target #2: The Inflammasome

Gout pathogenesis:
- Super saturated serum levels of uric acid lead to crystal formation and deposits in joints
- Crystals are engulfed by macrophages
- Macrophages release inflammatory cytokines
- Recruit more inflammatory cells and perpetuate joint inflammation

How do inert UA crystals lead to inflammation?

How does uric acid lead to inflammation???

- The “adaptive” immune system distinguishes self from non-self in a highly antigen-specific manner
  - Takes time to mount a naïve antigen-specific response to a specific microbial infection
  - For ex., vaccines can take weeks to become protective

- Arm of immune system can “innately” distinguish foreign microbial molecules from self
  - Patterns are common to many infections and not antigen/pathogen specific (endotoxin, flagella, etc.)
  - Leads to rapid inflammation (even septic shock) that acts as “speed bump” until adaptive immunity kicks in
  - Jump starts adaptive immune response (the need to add adjuvant to a vaccine)

Toll Like Receptors and Their Ligands

Pro IL-1 Activation

- Pro-IL-1 is inactive, but capable of being rapidly metabolized to active IL-1

- Machinery that activates pro IL-1 to active IL-1 is called the inflammasome
2nd “Danger” signal

- Activation of “pattern” receptors primes inflammatory response but does not activate it
  - Don’t want to become septic to one’s own commensal flora!
  - Production of inactive pro-IL 1β into cytoplasm that must be cleaved to active cytokine

- 2nd signal is required to distinguish pathogen from non-pathogen
  - Infected cells release their own cellular contents (eg. DNA/purines)
  - Uric acid is a danger signal!!!
Canakinumab (CK) vs. Triamcinolone
So et al. A&R 2010

- CK administered as one of 5 single doses
  - Previous gout flare
  - Acute gout flare <5 days
  - Inability to take other acute gout therapy

- Primary endpoint: find dose of CK equivalent to triamcinolone for reduction of pain at 72 hours

- No equivalent dose! All canakinumab doses superior to triamcinolone at 72 hours

Time to First Gout Flare
So et al. A&R 2010

Secondary endpoints:
- 8 week reduction in gout flares
- Time to 50% reduction in pain
- Reduction in serum inflammatory markers
- Patient and physician global assessments
- Use of other gout therapies

Not Quite Ready for Prime Time

FDA rejects expanded use of Regeneron drug for gout
Published July 31, 2012

Regeneron Pharmaceuticals Inc said U.S. regulators have denied approval for it to expand use of its Arcalyst drug to prevent gout flares, asking that the company provide more clinical data. The rejection follows a unanimous vote against the drug's approval in early May by advisors to the U.S. Food and Drug Administration, with panel members expressing concern that the company had only done a 16-week study.

FDA Panel Votes Against Gout Drug
By THOMAS M. BURTON
WASHINGTON—The Food and Drug Administration is grappling with the novel question of whether a Novartis AG NVS +0.97% gout-pain drug should be marketed when patients receiving just one injection had a higher rate of serious infections in clinical studies. An FDA advisory committee Tuesday voted 11-1 against approving the drug, called Iliaris, because of the safety concerns.

Advances in Therapies for Gout: Summary

- Gout is an ancient disease for whom modern therapy is finally available
  - Well managed by internists and PCPs who use standard therapy appropriately for acute vs. chronic gout
- New therapies are available
  - Febuxostat (allopurinol refractory, intolerant, or contraindicated)
  - Pegylated uricase: severe tophaceous disease
  - IL-1 blocking biologic therapy for the most severe disease
- Rheumatology referral appropriate for difficult to manage cases
The future is bright for those with gout who do not go extinct

canakinumab